This systematic review is the first to provide an extensive overview ofmiRNA validated in previous in vivo studies with the potential of predictingfavourable response to current neoadjuvant treatment strategies for patients beingtreated for HER2+ breast cancer. Here, ERBB2 is linked to breast cancer.